Human development

Lighthouse Guild Announces College Scholarships to 16 Students Who Are Blind

Retrieved on: 
星期二, 六月 4, 2024
Eastern Oregon University, Dream, Therapy, Student, Nursing, Science, Software, Social, Epidemiology, Organization, Lighthouse, Human development, Business, University, Face, School, Education, History, Master of Fine Arts, Person-centered therapy, Georgia Tech, Stanford University, Lighthouse Guild, Scheller College of Business, MFA, Tech, Autumn

New York, June 04, 2024 (GLOBE NEWSWIRE) -- Lighthouse Guild is awarding college scholarships of $10,000 each to 16 students from across the country who are legally blind and will be entering college or attending graduate school in the Fall.

Key Points: 
  • New York, June 04, 2024 (GLOBE NEWSWIRE) -- Lighthouse Guild is awarding college scholarships of $10,000 each to 16 students from across the country who are legally blind and will be entering college or attending graduate school in the Fall.
  • Since 2005, Lighthouse Guild’s Scholarship Program has awarded over $2.8 million in college scholarships to students who are legally blind.
  • “Students who are visually impaired can face particular challenges as they pursue their higher education goals,” said Dr. Calvin W. Roberts, President and CEO of Lighthouse Guild.
  • She is the recipient of the Dr. Neil S. Patel Memorial Scholarship, awarded by Lighthouse Guild to outstanding students who aspire to support underserved populations.

Digital Infuzion Welcomes Dr. Davyd Chung as Chief Growth Officer to Spearhead Strategic Expansion

Retrieved on: 
星期一, 五月 6, 2024
Public, University, Executive, Bangladesh Technical Education Board, HHS, DHA, NIH, UIC, Biomedical Research, DLH, NICHD, Growth, Doctor of Philosophy, National Cancer Institute, Molecular biology, Defense Health Agency, NCI, Champaign–Urbana metropolitan area, Human development, Defense, Nursing

ROCKVILLE, Md., May 6, 2024 /PRNewswire-PRWeb/ -- Joining the team on April 8, Dr. Davyd Chung brings over two decades of distinguished expertise in strategic growth and business development within the health sector.

Key Points: 
  • Digital Infuzion, a leader in health information technology solutions, is thrilled to announce the appointment of Dr. Davyd Chung as its new Chief Growth Officer.
  • Digital Infuzion is confident that Dr. Chung's strategic insights and leadership will propel the company towards new horizons of success and innovation in the health IT sector.
  • ROCKVILLE, Md., May 6, 2024 /PRNewswire-PRWeb/ -- Joining the team on April 8, Dr. Davyd Chung brings over two decades of distinguished expertise in strategic growth and business development within the health sector.
  • "Davyd's background in biomedical research and his proven track record in strategic growth are tremendous assets to us," said Hemant Virkar, CEO of Digital Infuzion.

Newark Native Mohamed Kamara Selected as 158th Draft Pick by the Miami Dolphins

Retrieved on: 
星期三, 五月 1, 2024
NFL, Miami Dolphins, Colorado State University, Central High School, Master, Bachelor, Athlete, National Football League Draft, Human development, CSU, Nursing

His athleticism continued post-graduation when he committed to Colorado State University (CSU) as a 3-star recruit.

Key Points: 
  • His athleticism continued post-graduation when he committed to Colorado State University (CSU) as a 3-star recruit.
  • At CSU, he exceeded expectations, earning the title of Mountain West Defensive Player of the Year.
  • On Saturday, April 27, 2024, his journey reached new heights when he was selected by the Miami Dolphins as the 158th pick in the NFL Draft, a testament to his skill, determination, and passion for the game.
  • "We are ecstatic to witness Mohamed Kamara's ascent in his football career," exclaimed Principal Terri Mitchell.

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Retrieved on: 
星期四, 四月 11, 2024
FDA, Birth control, Bangladesh Technical Education Board, NIH, Woman, Human services, NICHD, Trial of the century, Research, Development, CRADA, PCT, Human development, SAN

SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the publication of data from the postcoital test clinical study of Ovaprene in two original research articles in the journal Contraception.

Key Points: 
  • “Successful postcoital testing of Ovaprene: An investigational non- hormonal monthly vaginal contraceptive.” Contraception.
  • “Safety Testing of Ovaprene: an Investigational Non-Hormonal Monthly Vaginal Contraceptive.” Contraception.
  • Advance online publication, 110440. https://doi.org/10.1016/j.contraception.2024.110440
    “We are very pleased to have the postcoital test study results for our investigational, hormone-free intravaginal contraceptive Ovaprene published in a leading reproductive health journal,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience.
  • If successful, Daré expects the pivotal study to support marketing approvals of Ovaprene in the U.S. and other countries.

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Retrieved on: 
星期四, 三月 28, 2024
Cream, Dysmenorrhea, Patient, History, Bacteria, G&A, Vaginal discharge, IND, Bayer, Human development, Investment, Diclofenac, NSAID, Menstruation, Research, Hormone, Bacterial vaginosis, P-value, Webcast, SAN, NIH, Trial of the century, Pleasure, Woman, Breast cancer, Safety, Pharmacokinetics, Food, Development, Menopause, Nonsteroidal anti-inflammatory drug, HR, ARPA, VVA, Tamoxifen, FDA, Attention, CRADA, Female, Dyspareunia, Ecosystem, NICHD, Bangladesh Technical Education Board

SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2023 and provided a company update.

Key Points: 
  • In addition, we are excited about the increased attention that women’s health has received more broadly,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience.
  • In December 2023, Daré announced positive topline results from the Phase 1 study evaluating the pharmacokinetics (PK), safety, and exploratory efficacy of DARE-PDM1.
  • Financial Highlights for the Year Ended December 31, 2023 and 2024 Projections
    Cash and cash equivalents: $10.5 million at December 31, 2023.
  • Daré will host a conference call and live webcast today, March 28, 2024, at 4:30 p.m. Eastern Time to review financial results for the year ended December 31, 2023 and to provide a company update.

Sierra Metals Announces New Vice President, Health & Safety

Retrieved on: 
星期一, 三月 4, 2024
Mining, Minerals, Natural Resources, Occupational safety and health, Universidad de los Andes, Operational excellence, TSX, Postgraduate education, Master, Human development, Specialization, Engineering, Automation, SMT, Environment

Sierra Metals Inc. (TSX: SMT | OTCQX: SMTSF) (“Sierra Metals” or the “Company”) is pleased to announce the appointment of Mr. Astolfo Romero as Vice President, Health & Safety effective March 1, 2024 replacing Mr. Felix Guerra who is retiring after a very successful career in the mining industry.

Key Points: 
  • Sierra Metals Inc. (TSX: SMT | OTCQX: SMTSF) (“Sierra Metals” or the “Company”) is pleased to announce the appointment of Mr. Astolfo Romero as Vice President, Health & Safety effective March 1, 2024 replacing Mr. Felix Guerra who is retiring after a very successful career in the mining industry.
  • Ernesto Balarezo, CEO of Sierra Metals, commented, “We are very excited to have Astolfo join Sierra.
  • As a Postgraduate Teacher he received his Master's degree in Mining Management at GERENS and Pontificia Universidad Catolica del Peru.
  • Before joining Sierra, over the last 11 years, Mr. Romero served in multiple management positions in Volcan Compania Minera (Glencore) in areas such as Health & Safety, Operational Excellence, and Human Development.

The Foundation for the National Institutes of Health Launches First Public-Private Partnership for Early Detection of Preeclampsia

Retrieved on: 
星期一, 二月 12, 2024
Health, Family, Consumer, Other Health, Surgery, Other Science, Research, Parenting, Managed Care, General Health, Hospitals, Baby, Maternity, Science, Women, Master of Science, Bangladesh Technical Education Board, FNIH, Merck, Woman, Doctor of Philosophy, NICHD, NIH, Pregnancy, FDA, Partnership, Food, Pre-eclampsia, Mother, Ohio State University, Pappalysin-1, Letter, Risk, Human development, Cedars-Sinai Medical Center, Biomarker, Disorder, Organization, Task force, MPH, Thermo Fisher Scientific, PIGF, Child, Bill, DSM-IV codes, Mortality, George Washington University, Dietary supplement

The Foundation for the National Institutes of Health (FNIH) today announces the launch of a new public-private partnership to develop tools to identify pregnant women at high risk of early-onset preeclampsia.

Key Points: 
  • The Foundation for the National Institutes of Health (FNIH) today announces the launch of a new public-private partnership to develop tools to identify pregnant women at high risk of early-onset preeclampsia.
  • Preeclampsia is a serious pregnancy-related hypertensive disorder that can lead to maternal and neonatal deaths and long-term negative health outcomes.
  • The disorder is becoming more prevalent in the United States, with women of color more likely to be affected and experience poor outcomes.
  • Currently, preeclampsia risk is determined early in pregnancy using a combination of maternal medical history and clinical risk factors.

HUMAN CAPABILITY INITIATIVE CONVENES POWERHOUSE LINE-UP OF SPEAKERS FOR EXPERT-LED PLATFORM IN RIYADH

Retrieved on: 
星期三, 一月 31, 2024
University of Tokyo, Education, University, MENA, OECD, Human development, HCD, Region, HSBC, EVP, Crown prince, Social media, World Bank, HCI, World Bank Group, Private sector, UNESCO, Innovation, HRH, Conference, Management

150+ prominent speakers encompassing government officials, business & education leaders, entrepreneurs and experts will convene in Riyadh for the Human Capability Initiative

Key Points: 
  • 150+ prominent speakers encompassing government officials, business & education leaders, entrepreneurs and experts will convene in Riyadh for the Human Capability Initiative
    The breadth of high-level speakers and 6000+ global attendees demonstrate the collective impetus to unleash human capabilities potential through fostering intellectual dialogue in Riyadh.
  • RIYADH, Saudi Arabia, Jan. 31, 2024 /PRNewswire/ -- The Human Capability Initiative (HCI) is thrilled to announce key speakers for its forthcoming event taking place from the 28th – 29th February, 2024.
  • Bringing together luminaries from diverse sectors and backgrounds, these eminent industry leaders and experts will spearhead dynamic discussions centred around Human Capability Development (HCD) to prepare individuals for the challenges and opportunities of the future.
  • HCI's speaker line-up showcases the collective impetus across sectors to contribute to a sustainable global agenda that pioneers solutions for human capability development.

HUMAN CAPABILITY INITIATIVE CONVENES POWERHOUSE LINE-UP OF SPEAKERS FOR EXPERT-LED PLATFORM IN RIYADH

Retrieved on: 
星期三, 一月 31, 2024
University of Tokyo, Education, University, MENA, OECD, Human development, HCD, Region, HSBC, EVP, Crown prince, Social media, World Bank, HCI, World Bank Group, Private sector, UNESCO, Innovation, HRH, Conference, Management

150+ prominent speakers encompassing government officials, business & education leaders, entrepreneurs and experts will convene in Riyadh for the Human Capability Initiative

Key Points: 
  • 150+ prominent speakers encompassing government officials, business & education leaders, entrepreneurs and experts will convene in Riyadh for the Human Capability Initiative
    The breadth of high-level speakers and 6000+ global attendees demonstrate the collective impetus to unleash human capabilities potential through fostering intellectual dialogue in Riyadh.
  • RIYADH, Saudi Arabia, Jan. 31, 2024 /PRNewswire/ -- The Human Capability Initiative (HCI) is thrilled to announce key speakers for its forthcoming event taking place from the 28th – 29th February, 2024.
  • Bringing together luminaries from diverse sectors and backgrounds, these eminent industry leaders and experts will spearhead dynamic discussions centred around Human Capability Development (HCD) to prepare individuals for the challenges and opportunities of the future.
  • HCI's speaker line-up showcases the collective impetus across sectors to contribute to a sustainable global agenda that pioneers solutions for human capability development.

Daré Bioscience and Premier Research Extend Strategic Partnership to Accelerate the Clinical Development of Daré’s Novel Women’s Health Programs

Retrieved on: 
星期一, 十一月 20, 2023
Cream, Woman, SAN, Food, Human development, Research, FDA, United, CCTN, Birth, NICHD, Trial of the century, Partnership, Fine chemical, Pharmaceutical industry

The agreement was originally established with Health Decisions, Inc., which was acquired by Premier Research in 2021.

Key Points: 
  • The agreement was originally established with Health Decisions, Inc., which was acquired by Premier Research in 2021.
  • “In 2020, Daré and Premier Research conducted a successful Phase 3 clinical study of XACIATO™ (clindamycin phosphate) vaginal gel 2% despite the challenges posed by a global pandemic.
  • “Premier Research is thrilled to renew this partnership and continue our successful work with Daré,” said Michael Arlotto, Ph.D., Chief Operating Officer of Premier Research.
  • “This partnership underscores our joint commitment to advancing women’s health by supporting efforts to include women in clinical research and bring novel products to market.